Circulation. 2003;108:1707-1712
Published online before print September 22, 2003, doi: 10.1161/01.CIR.0000094734.67990.99
Published online before print September 22, 2003, doi: 10.1161/01.CIR.0000094734.67990.99
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2003;108:1707.)
© 2003 American Heart Association, Inc.
Clinical Investigations |
Increased Angiotensin-(1-7)–Forming Activity in Failing Human Heart Ventricles
Evidence for Upregulation of the Angiotensin-Converting Enzyme Homologue ACE2
From The Heart Institute and The Center for Cardiovascular Sciences, Albany Medical Center, Albany, NY (L.S.Z., R.S.K., B.W., Q.L., C.C.C.); Washington State University, Pullman, Wash (R.S.); The University of Colorado Health Sciences Center, Denver (M.R.B.); and Myomatrix Therapeutics, Rensselaer, NY (L.S.Z., Q.L.).
Correspondence to Lawrence S. Zisman, MD, FACC, The Heart Institute, MC 55, Albany Medical College, 47 New Scotland Ave, Albany, NY 12208. E-mail zismanl{at}mail.amc.edu
Received January 7, 2003; revision received May 13, 2003; accepted May 13, 2003.
Abstract
Background— The formation of angiotensin-(1-7) from either angiotensin (Ang) I or Ang II in failing human hearts is not well understood.
Methods and Results— Angiotensinase activity in left and right ventricular membranes from 14 idiopathic dilated cardiomyopathy (IDC), 8 primary pulmonary hypertension (PPH), and 13 nonfailing human hearts was measured with either 125I-Ang I or 125I-Ang II as substrate. Ang-(1-7)–forming activity from 125I-Ang I was inhibited by thiorphan. With 125I-Ang II as substrate, Ang-(1-7) formation was inhibited by the ACE2-specific inhibitor C16. Western blotting with an anti-ACE2 antibody confirmed the presence of ACE2. Angiotensinase activity with 125I-Ang I as substrate was increased in failing IDC left ventricles (LVs) compared with nonfailing LVs (P<0.001). Ang-(1-7)–forming activity with 125I-Ang II as substrate was increased in both failing LVs and right ventricles (RVs) of IDC hearts and only in failing RVs of PPH hearts (PPH LV, 51.12±5.25; PPH RV, 89.97±11.21; IDC LV, 139.7±21.96; and IDC RV, 192.7±5.43; NF LV, 32.89±5.38; NF RV 40.49±10.66 fmol/min per milligram (P<0.05 PPH RV versus PPH LV; P<0.05 PPH RV versus NF RV; P<0.001 IDC LV versus NF LV; P<0.001 IDC RV versus NF RV).
Conclusions— Ang-(1-7)–forming activity from both Ang I and Ang II was increased in failing human heart ventricles but was mediated by at least two different angiotensinases. The first, which demonstrated substrate preference for Ang I, was neutral endopeptidase (NEP)-like. The second was ACE2, as demonstrated by Western blotting and inhibition of activity with C16.
Key Words: angiotensin • enzymes • cardiomyopathy
This article has been cited by other articles:
 |
|
 |
|
  A. J. Ferreira, V. Shenoy, Y. Yamazato, S. Sriramula, J. Francis, L. Yuan, R. K. Castellano, D. A. Ostrov, S. P. Oh, M. J. Katovich, et al. Evidence for Angiotensin-converting Enzyme 2 as a Therapeutic Target for the Prevention of Pulmonary Hypertension Am. J. Respir. Crit. Care Med., June 1, 2009; 179(11): 1048 - 1054. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. W. Lai, R. A. Lew, M. A. Yarski, F.-T. Mu, R. K. Andrews, and A. I. Smith The Identification of a Calmodulin-Binding Domain within the Cytoplasmic Tail of Angiotensin-Converting Enzyme-2 Endocrinology, May 1, 2009; 150(5): 2376 - 2381. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Guy, D. W. Lambert, A. J. Turner, and K. E. Porter Functional angiotensin-converting enzyme 2 is expressed in human cardiac myofibroblasts Exp Physiol, May 1, 2008; 93(5): 579 - 588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Garabelli, J. G. Modrall, J. M. Penninger, C. M. Ferrario, and M. C. Chappell Distinct roles for angiotensin-converting enzyme 2 and carboxypeptidase A in the processing of angiotensins within the murine heart Exp Physiol, May 1, 2008; 93(5): 613 - 621. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Hernandez Prada, A. J. Ferreira, M. J. Katovich, V. Shenoy, Y. Qi, R. A.S. Santos, R. K. Castellano, A. J. Lampkins, V. Gubala, D. A. Ostrov, et al. Structure-Based Identification of Small-Molecule Angiotensin-Converting Enzyme 2 Activators as Novel Antihypertensive Agents Hypertension, May 1, 2008; 51(5): 1312 - 1317. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. H. Zucker Angiotensin-Converting Enzyme 2: A New Player in Central Sympathetic Regulation? Circ. Res., March 28, 2008; 102(6): 628 - 629. [Full Text] [PDF]
|
|
|
|
|
|
S. Der Sarkissian, J. L. Grobe, L. Yuan, D. R. Narielwala, G. A. Walter, M. J. Katovich, and M. K. Raizada Cardiac Overexpression of Angiotensin Converting Enzyme 2 Protects the Heart From Ischemia-Induced Pathophysiology Hypertension, March 1, 2008; 51(3): 712 - 718. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. G. Haworth The cell and molecular biology of right ventricular dysfunction in pulmonary hypertension Eur. Heart J. Suppl., December 1, 2007; 9(suppl_H): H10 - H16. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. deS. Senanayake, J. Drazba, K. Shadrach, A. Milsted, E. Rungger-Brandle, K. Nishiyama, S.-I. Miura, S. Karnik, J. E. Sears, and J. G. Hollyfield Angiotensin II and Its Receptor Subtypes in the Human Retina Invest. Ophthalmol. Vis. Sci., July 1, 2007; 48(7): 3301 - 3311. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Trask, D. B. Averill, D. Ganten, M. C. Chappell, and C. M. Ferrario Primary role of angiotensin-converting enzyme-2 in cardiac production of angiotensin-(1-7) in transgenic Ren-2 hypertensive rats Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H3019 - H3024. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Wakahara, T. Konoshita, S. Mizuno, M. Motomura, C. Aoyama, Y. Makino, N. Kato, I. Koni, and I. Miyamori Synergistic Expression of Angiotensin-Converting Enzyme (ACE) and ACE2 in Human Renal Tissue and Confounding Effects of Hypertension on the ACE to ACE2 Ratio Endocrinology, May 1, 2007; 148(5): 2453 - 2457. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Keidar, M. Kaplan, and A. Gamliel-Lazarovich ACE2 of the heart: From angiotensin I to angiotensin (1-7) Cardiovasc Res, February 1, 2007; 73(3): 463 - 469. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Diez-Freire, J. Vazquez, M. F. Correa de Adjounian, M. F. R. Ferrari, L. Yuan, X. Silver, R. Torres, and M. K. Raizada ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR Physiol Genomics, January 12, 2007; 27(1): 12 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A.S. Santos, C. H. Castro, E. Gava, S. V.B. Pinheiro, A. P. Almeida, R. D. de Paula, J. S. Cruz, A. S. Ramos, K. T. Rosa, M. C. Irigoyen, et al. Impairment of In Vitro and In Vivo Heart Function in Angiotensin-(1-7) Receptor Mas Knockout Mice Hypertension, May 1, 2006; 47(5): 996 - 1002. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Yamamoto, M. Ohishi, T. Katsuya, N. Ito, M. Ikushima, M. Kaibe, Y. Tatara, A. Shiota, S. Sugano, S. Takeda, et al. Deletion of Angiotensin-Converting Enzyme 2 Accelerates Pressure Overload-Induced Cardiac Dysfunction by Increasing Local Angiotensin II Hypertension, April 1, 2006; 47(4): 718 - 726. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Danilczyk and J. M. Penninger Angiotensin-Converting Enzyme II in the Heart and the Kidney Circ. Res., March 3, 2006; 98(4): 463 - 471. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Ferrario, A. J. Trask, and J. A. Jessup Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2281 - H2290. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Iwata, R. T. Cowling, D. Gurantz, C. Moore, S. Zhang, J. X.-J. Yuan, and B. H. Greenberg Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects Am J Physiol Heart Circ Physiol, December 1, 2005; 289(6): H2356 - H2363. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. J. Warner, R. A. Lew, A. I. Smith, D. W. Lambert, N. M. Hooper, and A. J. Turner Angiotensin-converting Enzyme 2 (ACE2), But Not ACE, Is Preferentially Localized to the Apical Surface of Polarized Kidney Cells J. Biol. Chem., November 25, 2005; 280(47): 39353 - 39362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Karram, A. Abbasi, S. Keidar, E. Golomb, I. Hochberg, J. Winaver, A. Hoffman, and Z. Abassi Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure Am J Physiol Heart Circ Physiol, October 1, 2005; 289(4): H1351 - H1358. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Tallant, C. M. Ferrario, and P. E. Gallagher Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor Am J Physiol Heart Circ Physiol, October 1, 2005; 289(4): H1560 - H1566. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. W. Lambert, M. Yarski, F. J. Warner, P. Thornhill, E. T. Parkin, A. I. Smith, N. M. Hooper, and A. J. Turner Tumor Necrosis Factor-{alpha} Convertase (ADAM17) Mediates Regulated Ectodomain Shedding of the Severe-acute Respiratory Syndrome-Coronavirus (SARS-CoV) Receptor, Angiotensin-converting Enzyme-2 (ACE2) J. Biol. Chem., August 26, 2005; 280(34): 30113 - 30119. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. S. Zisman Myocardial infarction increases ACE2 expression in rat and humans: reply Eur. Heart J., June 1, 2005; 26(11): 1141 - 1142. [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Ferrario, J. Jessup, M. C. Chappell, D. B. Averill, K. B. Brosnihan, E. A. Tallant, D. I. Diz, and P. E. Gallagher Effect of Angiotensin-Converting Enzyme Inhibition and Angiotensin II Receptor Blockers on Cardiac Angiotensin-Converting Enzyme 2 Circulation, May 24, 2005; 111(20): 2605 - 2610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Katovich, J. L. Grobe, M. Huentelman, and M. K. Raizada Angiotensin-converting enzyme 2 as a novel target for gene therapy for hypertension Exp Physiol, May 1, 2005; 90(3): 299 - 305. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Burrell, J. Risvanis, E. Kubota, R. G. Dean, P. S. MacDonald, S. Lu, C. Tikellis, S. L. Grant, R. A. Lew, A. I. Smith, et al. Myocardial infarction increases ACE2 expression in rat and humans Eur. Heart J., February 2, 2005; 26(4): 369 - 375. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. S. Zisman ACE and ACE2: a tale of two enzymes Eur. Heart J., February 2, 2005; 26(4): 322 - 324. [Full Text] [PDF]
|
|
|
|
 |
|
 N. Li, J. Zimpelmann, K. Cheng, J. A. Wilkins, and K. D. Burns The role of angiotensin converting enzyme 2 in the generation of angiotensin 1-7 by rat proximal tubules Am J Physiol Renal Physiol, February 1, 2005; 288(2): F353 - F362. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Zhong, D.-Y. Huang, Y.-M. Yang, Y.-F. Li, G.-F. Liu, X.-H. Song, and K. Du Upregulation of Angiotensin-Converting Enzyme 2 by All-trans Retinoic Acid in Spontaneously Hypertensive Rats Hypertension, December 1, 2004; 44(6): 907 - 912. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Huentelman, J. Zubcevic, J. A. Hernandez Prada, X. Xiao, D. S. Dimitrov, M. K. Raizada, and D. A. Ostrov Structure-Based Discovery of a Novel Angiotensin-Converting Enzyme 2 Inhibitor Hypertension, December 1, 2004; 44(6): 903 - 906. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. C. Douglas, M. K. O'Bryan, M. P. Hedger, D. K. L. Lee, M. A. Yarski, A. I. Smith, and R. A. Lew The Novel Angiotensin-Converting Enzyme (ACE) Homolog, ACE2, Is Selectively Expressed by Adult Leydig Cells of the Testis Endocrinology, October 1, 2004; 145(10): 4703 - 4711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. S. Zisman, G. E. Meixell, M. R. Bristow, and C. C. Canver Angiotensin-(1-7) Formation in the Intact Human Heart: In Vivo Dependence on Angiotensin II as Substrate Circulation, October 7, 2003; 108(14): 1679 - 1681. [Abstract] [Full Text] [PDF]
|
|